Should We Measure CSF Complement Levels in Patients With MOGAD?
作者信息
Moseley Carson E, Zamvil Scott S
机构信息
From the Department of Neurology (C.E.M.), Weill Institute for Neurosciences; Department of Neurology (S.S.Z.), Weill Institute for Neurosciences, and Program in Immunology, University of California, San Francisco.
出版信息
Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200302. doi: 10.1212/NXI.0000000000200302. Epub 2024 Aug 12.
Abstract
摘要
相似文献
1
Should We Measure CSF Complement Levels in Patients With MOGAD?我们是否应该检测视神经脊髓炎谱系障碍（MOGAD）患者的脑脊液补体水平？
Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200302. doi: 10.1212/NXI.0000000000200302. Epub 2024 Aug 12.
2
Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.补体激活谱可预测髓鞘少突胶质细胞糖蛋白抗体相关疾病的临床结局。
Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200340. doi: 10.1212/NXI.0000000000200340. Epub 2024 Dec 11.
3
Serum NfL and EGFR/NfL ratio mRNAs as biomarkers for phenotype and disease severity of myelin oligodendrocyte glycoprotein IgG-associated disease.血清 NfL 和 EGFR/NfL 比值 mRNA 作为髓鞘少突胶质细胞糖蛋白 IgG 相关疾病表型和疾病严重程度的生物标志物。
Front Immunol. 2024 May 14;15:1388734. doi: 10.3389/fimmu.2024.1388734. eCollection 2024.
4
Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.脑脊液中髓鞘少突胶质细胞糖蛋白-IgG：检测的临床意义及其与残疾的相关性。
Neurol Neuroimmunol Neuroinflamm. 2021 Oct 28;9(1). doi: 10.1212/NXI.0000000000001095. Print 2022 Jan.
5
The value of CSF diagnostic and prognostic biomarkers in NMOSD and MOGAD in real-life use.脑脊液诊断和预后生物标志物在视神经脊髓炎谱系障碍和髓鞘少突胶质细胞糖蛋白抗体相关疾病实际应用中的价值
Mult Scler Relat Disord. 2025 Feb;94:106302. doi: 10.1016/j.msard.2025.106302. Epub 2025 Jan 30.
6
Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.血浆补体 3 和补体 4 是鉴别 NMOSD 与 MOGAD 的有前途的生物标志物，与 NMOSD 中的血脑屏障破坏有关。
Front Immunol. 2022 Jul 11;13:853891. doi: 10.3389/fimmu.2022.853891. eCollection 2022.
7
Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.MOGAD 和 AQP4-IgG+NMOSD 中 C5 裂解后的不同补体激活模式。
Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200293. doi: 10.1212/NXI.0000000000200293. Epub 2024 Aug 12.
8
Permeability of the blood-CSF barrier in MOGAD: clinical correlation based on the 2023 diagnostic criteria.视神经脊髓炎谱系障碍（MOGAD）中血脑屏障的通透性：基于2023年诊断标准的临床相关性
Ann Med. 2025 Dec;57(1):2488181. doi: 10.1080/07853890.2025.2488181. Epub 2025 Apr 9.
9
Contributions of CSF interleukin-6 elevation to the pathogenesis of myelin oligodendrocyte glycoprotein antibody-associated disease.脑脊液白细胞介素-6 升高对髓鞘少突胶质细胞糖蛋白抗体相关疾病发病机制的影响。
Mult Scler. 2024 Jul;30(8):977-982. doi: 10.1177/13524585241254731. Epub 2024 May 23.
10
Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.血清神经丝轻链和 GFAP 与水通道蛋白 4 或髓鞘少突胶质细胞糖蛋白抗体阳性的炎症性疾病的严重程度相关。
Front Immunol. 2021 Mar 16;12:647618. doi: 10.3389/fimmu.2021.647618. eCollection 2021.
本文引用的文献
1
Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.MOGAD 和 AQP4-IgG+NMOSD 中 C5 裂解后的不同补体激活模式。
Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200293. doi: 10.1212/NXI.0000000000200293. Epub 2024 Aug 12.
2
Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders.髓鞘少突胶质细胞糖蛋白抗体相关疾病的病理学：与多发性硬化症和水通道蛋白4抗体阳性视神经脊髓炎谱系障碍的比较。
Front Neurol. 2023 Jul 21;14:1209749. doi: 10.3389/fneur.2023.1209749. eCollection 2023.
3
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.髓鞘少突胶质细胞糖蛋白抗体相关性疾病的诊断：国际 MOGAD 专家组提出的标准。
Lancet Neurol. 2023 Mar;22(3):268-282. doi: 10.1016/S1474-4422(22)00431-8. Epub 2023 Jan 24.
4
More Efficient Complement Activation by Anti-Aquaporin-4 Compared With Anti-Myelin Oligodendrocyte Glycoprotein Antibodies.与抗髓鞘少突胶质细胞糖蛋白抗体相比，抗水通道蛋白 4 抗体更有效地激活补体。
Neurol Neuroimmunol Neuroinflamm. 2022 Nov 22;10(1). doi: 10.1212/NXI.0000000000200059. Print 2023 Jan.
5
Neuromyelitis Optica Spectrum Disorder.视神经脊髓炎谱系障碍
N Engl J Med. 2022 Aug 18;387(7):631-639. doi: 10.1056/NEJMra1904655.
6
Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.髓鞘少突胶质细胞糖蛋白抗体相关性疾病：一项免疫病理学研究。
Brain. 2020 May 1;143(5):1431-1446. doi: 10.1093/brain/awaa102.
7
The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody.中枢神经系统炎症性脱髓鞘病伴髓鞘少突胶质细胞糖蛋白自身抗体的病理学。
Acta Neuropathol. 2020 May;139(5):875-892. doi: 10.1007/s00401-020-02132-y. Epub 2020 Feb 11.
8
B cells in autoimmune and neurodegenerative central nervous system diseases.自身免疫性和神经退行性中枢神经系统疾病中的 B 细胞。
Nat Rev Neurosci. 2019 Dec;20(12):728-745. doi: 10.1038/s41583-019-0233-2. Epub 2019 Nov 11.
9
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.抗水通道蛋白 4 抗体阳性视神经脊髓炎谱系疾病的治疗
N Engl J Med. 2019 Aug 15;381(7):614-625. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.
10
Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?MOG 抗体阳性、AQP4 抗体阴性的视神经脊髓炎谱系疾病是否需要诊断为 NMOSD？
Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e62. doi: 10.1212/NXI.0000000000000062. eCollection 2015 Feb.
Zotero 插件